rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ARS Pharmaceuticals, Inc.

SPRY · Nasdaq

Health CarePharmaceuticalsNot moving yet

SPRY stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 39.6% below that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.2M
Officials’ trades on record
0
Institutions holding
193 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$17.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 4
WhoDidSharesTraded
Alexander A. FitzpatrickChief Legal Officersold3,355at $10.0012 Jun 2026filed 12 Jun 2026
Eric KarasChief Commercial Officersold25,000at $10.0012 Jun 2026filed 12 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders193+4 on the quarter
New · exited37 · 33
Reported value$711.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 202610,860,977$87.0M00.0%
Rubric Capital Management LPadded · filed 14 Aug 20268,540,861$68.4M+540,861+6.8%
ORBIMED ADVISORS LLCunchanged · filed 14 Aug 20268,288,510$66.4M00.0%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 20267,503,812$60.1M00.0%
BlackRock, Inc.added · filed 7 Aug 20265,311,319$42.5M+299,065+6.0%
Tyro Capital Management LLCadded · filed 13 Aug 20264,459,337$35.7M+1,490,738+50.2%
Aberdeen Group plcadded · filed 31 Jul 20264,170,629$33.4M+57,012+1.4%
SR One Capital Management, LPunchanged · filed 12 Aug 20264,012,903$32.1M00.0%
STATE STREET CORPadded · filed 7 Aug 20263,730,623$29.9M+85,657+2.4%
Capital World Investorsnew · filed 12 Aug 20262,754,931$22.1M+2,754,931
31 Mar 2023 – 30 Jun 2026
75132189Mar 23Dec 23Dec 24Sep 25Jun 26

News

Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class ...pr-inside.com · 2 Oct 2026SPRY LAWSUIT ALERT: Levi & Korsinsky Notifies ARS Pharmaceuticals, ...pr-inside.com · 29 Sep 2026ARS Pharmaceuticals, Inc. (SPRY) Lawsuit - Investors Urged to Contact ...pr-inside.com · 29 Sep 2026SPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. ...gazettextra.com · 26 Sep 2026Class Action Alert: Levi & Korsinsky Reminds ARS Pharmaceuticals (SPRY) ...pr-inside.com · 24 Sep 2026October 5, 2026 Deadline: Join Class Action Lawsuit Against ARS Pharmaceuticals, ...pr-inside.com · 21 Sep 2026Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky ...pr-inside.com · 19 Sep 2026ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ...pr-inside.com · 18 Sep 2026

Everyone who traded it

Donn Casale Company insiderPresident and CEO · last 1 Oct 20260 · 0
Margaret Ekins Smith Company insiderChief Commercial Officer · last 1 Sep 20260 · 0
Brent L. Saunders Company insiderDirector · last 24 Jun 20260 · 1
Laura Shawver Company insiderDirector · last 24 Jun 20260 · 22
Michael Kelly Company insiderDirector · last 24 Jun 20260 · 0
Peter A. Thompson Company insiderDirector · last 24 Jun 20262 · 4
Peter Kolchinsky Company insiderDirector, 10% owner · last 24 Jun 20260 · 0
Phillip M. Schneider Company insiderDirector · last 24 Jun 20260 · 0
Pratik Shah Company insiderDirector · last 24 Jun 20260 · 0
RA CAPITAL MANAGEMENT, L.P. Company insiderDirector, 10% owner · last 24 Jun 20264 · 0
Rajeev Dadoo Company insiderDirector · last 24 Jun 20260 · 0
Saqib Islam Company insiderDirector · last 24 Jun 20260 · 0

Same industry

PCRX Pacira BioSciencesLeading+45%
TTRX Turn TherapeuticsLeading+40%
CORT Corcept TherapeuticsLeading+34%
ETON Eton PharmaceuticalsLeading+23%
AMRX Amneal PharmaceuticalsLeading+21%
TEVA Teva Pharmaceutical IndustriesLeading+19%
ABBV AbbVieLeading+19%
LLY Eli Lilly andLeading+13%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-213%
Free cash flow marginFY 2025 · to 31 Dec 2025-203%
Return on capital employedFY 2025 · to 31 Dec 2025-62.2%
Debt to equityFY 2025 · to 31 Dec 20250.84×
Research spendFY 2025 · to 31 Dec 202515.6%
Share count trendFY 2025 · to 4 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$41.3M
Free cash flowFY 2025 · to 31 Dec 2025−$171.2M

Analyst forecasts

No analyst forecasts yet.